SUIC Worldwide acquires 51% of Taiwan medical-device firm Vision Renu for 30M shares

SUIC Worldwide Holdings Ltd.

SUIC issued 30M shares (35% fully diluted) to acquire 51% of Vision Renu; implied enterprise value $50M based on $0.85/share.
New leadership: Chen King Te named Chairman/CEO, Kho Jean Jean CFO, Dongsheng Zou director; Lo, Wang, Tan resigned.
Vision Renu products: presbyopia laser (FDA approval pending) and TMS depression device (Taiwan-approved); 150-unit 2026 orders.
Pro forma 2025: combined revenue $163K, net loss attributable to SUIC $341K, EPS -$0.0082; goodwill $47.98M recorded.

item 1.01 item 2.01 item 5.01 item 5.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.